Abstract:
Aim: The aim of this study was to assess the effects and risk-benefit of antiviral therapy in
cirrhotic patients operated for portal hypertension.
Methods: This study included 38 patients with viral-related liver cirrhosis,out of whom 18
patients (Group A) received IFN and splenectomy and 20 patients (Group B) recived only IFN therapy.
Results: The effects of splenectomy and IFN therapy on peripheral blood counts and liver
function were evaluated. Platelet and leukocyte counts were significantly higher in patients with
splenectomy compared to the group that recived only antiviral therapy. The antiviral therapy was well
tolerated with no severe complications in surgical group (group A):16 patients had completed IFN
therapy, one patient discontinued because of septic shock and one because of thrombocytopenia. While
in group B from total of 20 patients, 9 subjects had discontinued: because of thrombocytopenia-5, and 4
because absence of viral response.
The viral response estimated at least 6 months after IFN therapy showed a sustained viral
response in 55,5% of patients in group A and 25 % in group B.
Conclusions: IFN- based therapy following splenectomy had an advantage in the maintenence
of higher platelet and leukocyte counts, and splenectomy caused an increase in adherence to antiviral
therapy. The combination therapy of splenectomy and long-term IFN significantly improved survival
rate in patients with advanced HCV-related cirrhosis and portal hypertension.
Description:
Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016